CA-BIOCELL-TECHNOLOGY
13.6.2019 02:53:04 CEST | Business Wire | Press release
BioCell Technology, LLC, a branded dietary ingredient supplier, today announced the presentation of The Effects of Skin Aging Associated with the Use of BioCell Collagen® in Healthy Adult Females: A Randomized, Double-blind, Placebo-controlled Clinical Trial . These results were presented in a poster session at the American Society for Nutrition (ASN) Nutrition 2019 on June 9, 2019, and are available at http://bit.ly/2WzhODi . This poster will be published as part of the proceedings of Nutrition 2019 by ASN. The manuscript of the study will be published in the online and print versions of the peer review journal Alternative Therapies in Health and Medicine (ATHM).
The goal of the study was to determine if a correlation existed between the effects of the dietary supplement, BioCell-Collagen®, with changes associated with skin aging. The study was a 128-female subject, 12-week, double-blind, placebo-controlled trial. Participants were randomly assigned to an intervention or a placebo. The intervention consisted of twice daily 500mg oral administration of BioCell Collagen®, a novel hydrolyzed chicken sternal cartilage extract dietary ingredient composed of a naturally-occurring matrix of collagen type-II peptides (≥300 mg), chondroitin sulfate (≥100 mg), and hyaluronic acid (≥50 mg).
For the 113 participants completing the study, BioCell Collagen® supplementation compared to a placebo resulted in:
- Significantly reduced facial lines and wrinkles (P = .019) and crow’s feet lines and wrinkles (P = .05)
- Increased skin elasticity (P = .008) and cutaneous collagen content (P < .001) by 12%
- Improved indicators associated with a more youthful skin appearance based on visual grading and wrinkle width (P = .046)
- Decreased skin dryness and erythema.
- No difference existed between the supplement and the placebo for skin surface water content or retention. The supplement was well tolerated, with no reported adverse reactions.
“We are very excited to publish the findings of our largest study to date, which further supports the efficacy of our flagship dietary ingredient BioCell Collagen®. Human clinical studies continue to be the gold standard for substantiating dietary supplement claims and we take pride that our licensed partners can take advantage,” said Suhail Ishaq, president of BioCell Technology.
The latest study validates an earlier pilot study that demonstrated similar results- Schwartz SR, Park J. Ingestion of BioCell Collagen®, a novel hydrolyzed chicken sternal cartilage extract; enhanced blood microcirculation and reduced facial aging signs. Clin Interven Aging . 2012; 7: 267-273.
“An impressive example of how a series of studies, capped by a randomized, double-blind, placebo-controlled, supports a ‘beauty from within’ claim in healthy women. Even more impressive was that the results remained statistically significant even after an intention-to-treat analysis was performed that included the few subjects that dropped out of the study. Such an analysis is seen in only about 15-20% of randomized, placebo-controlled blinded clinical studies published in leading medical journals,” said Alexander Schauss, PhD, FACN, CFS, Senior Director of Research at AIBMR Life Sciences, and the corresponding author.
“It is important that the supplement industry conducts research at the pinnacle of good science and this includes a double blind, properly populated study like this one,” said Stephen Schwartz, President and CEO of International Research Services, Inc.
About BioCell Collagen ®
BioCell Collagen® is a clinically tested branded dietary ingredient that promotes active joints, youthful-looking skin, and healthy connective tissues. BioCell Collagen® contains a patented composition of naturally occurring hydrolyzed collagen type II peptides, chondroitin sulfate and hyaluronic acid in a highly absorbable matrix form that has been the subject of numerous human clinical trials, including trials on safety, efficacy, and bioavailability. BioCell Collagen® is self-affirmed GRAS (Generally Recognized As Safe). BioCell Collagen® is non-GMO and free of gluten, soy, shellfish, fish, egg, milk, peanuts and sugar. BioCell Collagen® is made exclusively in the USA and Europe. For more information, visit www.BioCellCollagen.com .
About BioCell Technology, LLC
BioCell Technology is a research, product development, branding, and marketing company that manufactures innovative, science-based ingredients that have applications in dietary supplements, functional foods and cosmetics. The company licenses its branded ingredients to leading consumer packaged goods companies for use in their finished products. For more information visit www.BioCellTechnology.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190612005972/en/
Contact:
Suhail Ishaq President of BioCell Technology, LLC 714-632-1231
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Svante’s Solid Sorbent Filter Technology Named to Fast Company’s 2026 World Changing IdeasAwards List16.6.2026 16:00:00 CEST | Press release
The recognition highlights Svante’s nanoengineered filters for CO₂ capture and removal This year’s awards, featured on fastcompany.com, highlight 191 outstanding projects across 14 categories. Svante Technologies Inc. (Svante), a purpose-driven integrated carbon management company, today announced that its nanoengineered solid sorbent filter technology has been named to Fast Company’s 2026 World Changing Ideas list, one of the world’s most selective recognitions for innovations tackling climate and sustainability challenges. The honour recognizes Svante’s proprietary filter platform, which enables high-performance capture and removal of CO₂ from industrial emissions and the air, as well as other critical gas separation applications, particularly where chemical processes do not perform well. This year’s awards, featured on fastcompany.com, highlight 191 outstanding projects across 14 categories. A panel of Fast Company editors and reporters evaluated more than 1,500 entries based on the
AIRS Medical Welcomes Strategic Growth Investment from TA Associates to Accelerate Global Growth in AI-Powered MRI Solutions16.6.2026 16:00:00 CEST | Press release
Investment supports global expansion and continued innovation in AI-powered MRI technologies that help healthcare providers improve imaging efficiency, increase capacity and expand patient access AIRS Medical (“the Company”), a global leader in AI solutions for medical imaging, today announced a strategic growth investment from TA Associates (“TA”), a leading global private equity firm. The investment will help fuel AIRS Medical’s next phase of global expansion, advancement of its AI-powered radiology technology solutions and ongoing product innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616325248/en/ Founded in 2018, AIRS Medical develops AI-native magnetic resonance imaging (“MRI”) acceleration and reconstruction software designed to support MRI speed, image quality and workflow performance. Healthcare organizations and leading academic institutions are adopting AIRS Medical's technologies to expand imaging
Clearlake Capital Closes on $14.8 Billion to Capitalize on AI-Driven Transformation and Continue Sector-Focused Investment Strategy16.6.2026 15:00:00 CEST | Press release
Fund VIII Reflects Strong Global Investor Support for Clearlake’s Integrated Platform, Operational Value-Creation Model, and AI-Enabled Investment Approach Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced the successful close of its eighth flagship fund, Clearlake Capital Partners VIII (“Fund VIII”), alongside related co-investment vehicles and separately managed accounts. Together, these vehicles represent $14.8 billion of capital commitments and position Clearlake to continue investing behind the secular trends reshaping industries, including artificial intelligence, software modernization, digital transformation, and operational efficiency. The successful fundraise comes amid a highly competitive and selective fundraising environment for private markets and underscores continued investor confidence in Clearlake's different
Gurobi's Research Leadership Recognized Across Leading Scientific Organizations16.6.2026 15:00:00 CEST | Press release
Awards recognize foundational research that helped shape the fields of mixed-integer and nonlinear optimization—and reflect the company’s deep scientific roots. Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced recognitions received by Dr. Edward Rothberg and Dr. Andreas Wächter from leading academic and industry organizations for research that has had lasting impact on the field of optimization. “Gurobi was founded on a commitment to rigorous, applied optimization research,” said Dr. Oliver Bastert, CTO, Gurobi. “And these recognitions are a reflection of that legacy. The foundational work that Ed and Andreas produced continues to shape the field, and that same spirit of scientific innovation drives everything we do today.” Dr. Edward Rothberg, co-founder and Chairman of the Board at Gurobi, was recently honored with the INFORMS Test of Time Paper Award for his paper, “An Evolutionary Algorithm for Polishing Mixed Integer Programming Solutions.”
Airship Helps DIE ZEIT Turn Silent Advocates into 4.9-Star Rating16.6.2026 15:00:00 CEST | Press release
Leveraging Airship’s Customer Experience Platform, Germany’s leading digital news publisher transforms reader engagement and captures 822 active responses in a single day. Airship, the mobile-first customer experience company, today announced that DIE ZEIT, one of Germany’s largest and most prestigious publishers, has successfully transformed its mobile app presence, lifting the Google Play app store rating from 2.7 stars in early 2026 to a near-perfect 4.9 stars. At a time when many traditional publishers are seeing readership numbers plummet, DIE ZEIT is growing — reaching an all-time high circulation in 2025 and building a digital ecosystem around the brand. The majority of the publication’s readers are now digital, but the publication’s app store rating for DIE ZEIT didn’t match this momentum. DIE ZEIT was up against a universal challenge faced by digital product teams and customer experience executives globally: the "silent advocate" problem. While highly satisfied customers rarel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
